Half-year report · HY
3034.TEDINET S100X3IM
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥142.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥264.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥13.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.1bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥152.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥159.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥96.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥97.5bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥62.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥13.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥94.51 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.97 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥721m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥721m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.9bn |
| Health Insurance Pharmacyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥86.8bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥86.7bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥76m |
| Health Insurance Pharmacyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.1bn |
| Medical Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥7.7bn |
| Medical Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.1bn |
| Medical Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥644m |
| Medical Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥48.4bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥48.4bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥143.0bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥142.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥721m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥9.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest and dividends income ope cf | Prior1InterimDuration | -5000000 | JPY |
| Interest and dividends income ope cf | InterimDuration | -50000000 | JPY |
| Interest expenses ope cf | Prior1InterimDuration | 97000000 | JPY |
| Interest expenses ope cf | InterimDuration | 177000000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -1075000000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -1820000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | -2026000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | -4800000000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1InterimDuration | 288000000 | JPY |
| Decrease increase in accounts receivable other ope cf | InterimDuration | 1563000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1InterimDuration | -2357000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | InterimDuration | 3701000000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1InterimDuration | -1611000000 | JPY |
| Increase decrease in accounts payable other ope cf | InterimDuration | -130000000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1InterimDuration | -1023000000 | JPY |
| Increase decrease in accrued expenses ope cf | InterimDuration | -966000000 | JPY |
| Increase decrease in long term accounts payable other ope cf | Prior1InterimDuration | -146000000 | JPY |
| Increase decrease in long term accounts payable other ope cf | InterimDuration | -173000000 | JPY |
| Other net ope cf | Prior1InterimDuration | 1459000000 | JPY |
| Other net ope cf | InterimDuration | 139000000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | 1528000000 | JPY |
| Subtotal ope cf | InterimDuration | 8759000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 5000000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 49000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -97000000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -177000000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -958000000 | JPY |
| Income taxes paid ope cf | InterimDuration | -2446000000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 477000000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | 6186000000 | JPY |
| Payments into time deposits inv cf | Prior1InterimDuration | -5000000 | JPY |
| Payments into time deposits inv cf | InterimDuration | -104000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1InterimDuration | 26000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | InterimDuration | 13000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -997000000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -555000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1InterimDuration | 53000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | InterimDuration | 121000000 | JPY |
| Purchase of intangible assets inv cf | Prior1InterimDuration | -316000000 | JPY |
| Purchase of intangible assets inv cf | InterimDuration | -491000000 | JPY |
| Proceeds from redemption of investment securities inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from redemption of investment securities inv cf | InterimDuration | 10000000 | JPY |
| Collection of loans receivable inv cf | Prior1InterimDuration | 8000000 | JPY |
| Collection of loans receivable inv cf | InterimDuration | 12000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1InterimDuration | -59000000 | JPY |
| Payments for lease and guarantee deposits inv cf | InterimDuration | -68000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1InterimDuration | 88000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | InterimDuration | 59000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | -2368000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |